Home
Live Updates
Travere Therapeutics Reports Third Quarter 2023 Financial Results : comparemela.com
Travere Therapeutics Reports Third Quarter 2023 Financial Results
Received 430 new patient start forms for FILSPARI® in the third quarter of 2023; demand and payer coverage continued to grow Net product sales of FILSPARI...
Related Keywords
United States ,
Iceland ,
Liechtenstein ,
Norway ,
American ,
Nivi Nehra ,
Deric Dube ,
Naomi Eichenbaum ,
Mirum Pharmaceuticals ,
American Society Of Nephrology Kidney Week ,
Travere Therapeutics Inc ,
Corporate Communications ,
European Union ,
Program Updates ,
Drug Administration ,
Committee For Medicinal Products Human Use ,
Exchange Commission ,
Mission Pharmacal Company ,
Nasdaq ,
European Medicines Agency ,
Week Late Breakers ,
Travere Total Care ,
Continuing Operations ,
Quarter Ended September ,
American Society ,
Nephrology Kidney Week ,
New England Journal ,
New Drug Application ,
Medicinal Products ,
Human Use ,
Conditional Marketing Authorization ,
Inborn Errors ,
Annual Symposium ,
Par Pharmaceutical ,
Acid Product Portfolio ,
Travere Therapeutics ,
Important Safety Information ,
Endothelin Receptor Antagonists ,
Upper Limit ,
Fetal Toxicity ,
Full Prescribing Information ,
Private Securities Litigation Reform Act ,
Months Ended September ,
Markets ,
comparemela.com © 2020. All Rights Reserved.